• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Alerts

ACOG Guidance on Evaluation and Management of Endometriosis and Dysmenorrhea in Adolescents

image_pdfFavoriteLoadingFavorite

SUMMARY:

ACOG has released recommendations on the diagnosis and management of dysmenorrhea and endometriosis in adolescents.

The goals of therapy include symptom relief, suppression of disease progression, and protection of future fertility. Therapy must be individualized, and obstetrician–gynecologists should consider patient choice, the need for contraception, contraindications to hormone use, and potential adverse effects and counsel the adolescent and her family on treatment options.

  • Key Definitions
  • Evaluation
  • Management of Primary Dysmenorrhea
  • Negative Evaluation – Consider Endometriosis

Key Definitions

  • Primary dysmenorrhea
    • Painful menstruation in the absence of pelvic pathology
    • Starts 6–12 months after onset of menses
  • Secondary dysmenorrhea
    • Painful menstruation with pelvic pathology or medical condition
    • Most commonly caused by endometriosis
    • Less common causes
      • Aenomyosis | Infection (e.g., PID) | Fibroids | Müllerian structural anomalies leading to outlet obstruction | Ovarian cysts
    • Chronic pelvic pain
      • Pelvic pain ≥6 months
      • Timing: Constant | Intermittent |Cyclic | Acyclic

Symptoms

  • Associated with dysmenorrhea
    • Nausea and vomiting
    • Diarrhea
    • Headaches
    • Muscle cramps
    • Sleep disturbance
    • Premenstrual syndrome
  • Note: Endometriosis in adolescents may be associated with chronic acyclic nonmenstrual pain

Evaluation

Primary dysmenorrhea

  • Evaluation based on thorough history
    • pelvic exam not necessary if symptoms ‘only’ of primary dysmenorrhea

Secondary dysmenorrhea

  • Requires further evaluation and should be considered with the following reported symptoms
    • Severe dysmenorrhea immediately after menarche
    • Progressively worsening dysmenorrhea
    • Abnormal uterine bleeding
    • Mid-cycle or acyclic pain
    • Lack of response to empiric medical treatment
    • Dyspareunia
    • Personal or family history
      • Endometriosis | Genitourinary structural anomalies
      • Family history of endometriosis have up to a 10-fold increased risk
  • Work up for secondary dysmenorrhea
    • Consider pelvic examination
      • With proper education and counseling, “many adolescents who are not sexually active are able to tolerate a pelvic examination”
    • Ultrasound should be used as initial imaging modality
      • MRI may be helpful for follow up, but not as a primary imaging approach
    • If positive findings, manage and treat as appropriate

Note: Pelvic pain that persists for 3 to 6 months warrants further evaluation for other causes of chronic pelvic pain such as GI, GU, MSK or psychological

KEY POINTS:

Management of Primary Dysmenorrhea

Empiric treatment

  • NSAIDS
    • Ibuprofen
      • First Dose: 800 mg
      • Followed by 400-800 q8 mg every 8 hours PRN
    • Naproxen sodium
      • First Dose: 440-550 mg
      • Followed by 220-550 mg every 12 hours PRN
    • Mefenamic acid
      • First Dose: 500 mg
      • Followed by 250 mg every 6 hours PRN
    • Celecoxib (>18 years of age)
      • First Dose: 400 mg
      • Followed by 200 mg every 12 hours PRN
    • Hormonal Therapy
      • (1) Inadequate relief with NSAIDS or (2) Can be considered appropriate as first line therapy
    • Alternative nonpharmacologic therapies
      • “Given the low risk of harm and low cost of heat therapy and exercise, as well as the additional general health benefits of exercise, both options should be encouraged”
      • Dietary supplements (limited evidence)
        • Fenugreek | Ginger | Valerian | Zataria | Zinc sulphate | Fish oil Vitamin B1
        • Vit D: Conflicting evidence
      • TENS (Transcutaneous electrical nerve stimulation) | Acupuncture | Herbal preparations | Yoga
        • Limited evidence does not support use as first line treatment
        • Herbal treatments: Safety and efficacy unclear
      • Surgical therapies
        • Insufficient evidence to support use of surgical therapies for primary dysmenorrhea
        • Recommendation against ablation and hysterectomy

Consider Endometriosis in Refractory Cases

Diagnosis of endometriosis

  • Requires surgical/pathologic diagnosis
  • Patients/family may opt of medical management of endometriosis without surgical confirmation
  • ACOG recommends ‘shared decision making’
    • Benefits of laparoscopy
      • Only way to confirm and treat if endometriosis is the cause (tend to be early stage)
      • Other pathologies may be identified
    • Risks of laparoscopy
      • Typical surgical and anesthesia risks
    • If patient undergoing diagnostic laparoscopy for pelvic pain
      • Consider hormonal IUD at time of laparoscopy (even though not approved by FDA for treatment of endometriosis pain)
      • Evidence for benefit
        • Dysmenorrhea unresponsive to oral contraceptives
        • Endometriosis pain

Management of endometriosis

  • Conservative surgical therapy
  • NSAIDs for pain relief (not narcotics outside specialized pain unit)
  • Suppressive hormonal therapy
    • Continuous combined hormonal contraceptive
    • Progestin-only agent
    • 52 mg (hormonal contraceptive) LNG-IUS
  • If unresponsive to the above, consider
    • GnRH agonist with add back (0.625 mg CEE and 5 mg norethindrone acetate daily) for at least 6 months
      • Dual-energy X-ray absorptiometry scanning not necessary (if using GnRH <12 months)
      • Bone health: Dietary calcium | Vitamin D | Weight-bearing exercise
      • Continuous hormone-suppression therapy after GnRH completed

Learn More – Primary Sources:

ACOG Committee Opinion 760: Dysmenorrhea and Endometriosis in the Adolescent

Want to be notified when a new guideline is released?

Learn More »

image_pdfFavoriteLoadingFavorite

< Previous
All Alerts Posts
Next >

Related ObG Topics:

Evaluation and Treatment of Endometriosis
Can Exercise Alleviate Primary Dysmenorrhea?
Comparing IUD vs Implant for the Management of Endometriosis
Can Self-Acupressure Apps Relieve Dysmenorrhea?
Can Heat Treat Dysmenorrhea?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site